argenx SE

Welcome, everyone. I'm Allie Bratzel, one of the biotech analysts here at Piper Sandler. And it is my pleasure to introduce Argenix. So joining us today, we have CFO Karl Gubitz. The format of this is going to be fireside chat, but first I'm going to let Karl give us kind of an intro to the company, what's going on, and what to look forward to. So Karl, go ahead.

Thank you, Allie. It's a pleasure to be here. Thank you for the opportunity. At Arganix, I think things are going really well. We continue to execute for our shareholders. A few years ago, we laid out our vision for 2025. Happy to report that we've achieved all of those objectives. So that is why a few months ago at our R&D day, we laid out our new vision for 2030. And the headline of that new vision is 5, 10, 50. Starting with 50, 50,000 patients by 2030. I think that's a really ambitious but an achievable target, creating drugs with a differentiated outcome for 50,000 patients. Ten, ten is ten new indications on label, or ten indications on label by 2030, and five is five products, new products under development. I think that's a very ambitious plan and also at the R&D day we showed you some of our science. We showed some of our scientists were given the opportunity to present the science, which I think was all very exciting. To let investors see a little bit under the hood of the company. We also had the Q3 financial results. 573 million of product net sales. Really good quarter, very satisfied with that quarter, but also included the first quarter of our CIDP launch, which is our second indication, and I'm sure we'll talk about that a little bit later. And the last update maybe I'll give is on myositis. We gave you the results of a myositis phase two study. As a little bit of background, it was a seamless phase two, phase three for three subsets of myositis. And when we fully recruited the phase two part of it, we immediately started enrolling the phase three part of that study. And we announced the go, or continue if you like, for all three subsets of myositis. So that was also really exciting news. As we look forward to the end of the year and Christmas, we have no further catalyst to report. I think we're done for the year, but we will, of course, continue to execute for our shareholders on both the commercial front and on the clinical side. Thank you, Ali.

Great. So I think we'll start out digging in a little bit on myositis. You know, we didn't get a ton of data in the top line other than the study minutes endpoint showing a... improvement I mean total improvement score on all six core measures I guess can you kind of talk to what you viewed as the goal hurdle you had in place or what would what do you view as a clinically meaningful benefit in myositis yeah because it's a seamless phase two phase three we cannot and we don't want or we shouldn't from a regulatory point of view and from a competitive point of view